Research Scientist, Sr Research Associate Resume

Desired Industry: Biotech	SpiderID: 17781
Desired Job Location: South San Francisco, California	Date Posted: 12/17/2007
Type of Position: Full-Time Permanent	Availability Date: current
Desired Wage:
	U.S. Work Authorization: Yes
Job Level: Experienced with over 2 years experience	Willing to Travel: Yes, Less Than 25%
Highest Degree Attained: Doctoral	Willing to Relocate: Yes

Objective:
Research Scientist, or Senior Research Associate in Biotech or Pharmaceutical industry where I can use my 14 years' experiences of human disease biomarker discovery with genomic and/or proteomic technologies.

Experience:
Stanford University, Stanford, CA 1999-2007
Research Associate, Dr Thomas A. Stamey’s laboratory (PSA lab), Department of Urology, Stanford University, School of Medicine
Advanced prostate cancer biomarker discovery with proteomic technology
-Using 2-dimentional difference in gel electrophoresis system and mass spectrometry, analyzed proteins from grade 4/5 prostate cancer and BPHs. Identified 100 interesting proteins (some unreported) as potential markers. ELISA was performed in hundreds of clinical sera.
-Ran proteins from frozen tissues and sera. Applied laser-capture microarray technology for frozen sections, and affinity column for removal of abundant proteins in sera.
-Collaborated with ABI and SIGMA in high volume cancer serum and high volume BPH analysis with the depletion of top 20 abundant proteins and quantitative analysis with 4800 Plus MALDI TOF/TOF™ Analyzer.
-Collaborated with Ciphergen for SELDI-TOF analysis for total proteins from LCM treated cancer cells and BPH cells in 2000.
-Presented results in international meetings including AACR Annual Meeting, HUPO Annual Meeting and Mass Spectrometry Annual Meeting.

Advanced prostate cancer biomarker discovery with microarray technology
-In very successful collabration with Affymatrix, screened the global gene expressions from different categories of prostate cancers, as well as BPH, dysplasia and normal with 6500 FL chips and U133 chips.
-In combined effort of Dr Stamey, who introduced PSA for the diagnostics of prostate cancer, and Dr John McNeal, the top pathologist of prostate cancer, characterized differences in gene expression from different histological zones: peripheral zone, transitional zone, central zone and seminal vesicle.
-Awarded 2 patents.
-4 papers published.
-First to report hepsin and maspin were inversely expressed in cancers. Research highly praised by former NCI Director Dr. Andrew C. von Eschenbach. Our unique database is still used in identifying interesting genes for clinical trials.

Chinese Academy of Medical Sciences, Beijing, China 1993-1999
Research Associate/Graduated Student, Dr Shujun Cheng’s laboratory, Cancer Institute and Hospital, Hematology Institute and Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College
Early diagnostic biomarker discovery of bladder cancer with DNA genetic polymorphism analysis
-In international collaboration with JHU and MD Anderson Cancer Center, performed genomic DNA polymorphism research.
-Screened hundreds of microsatellite DNAs throughout human genome by PCR in human bladder cancers, both with urine and matched tissues, to find early biomarkers for diagnostics.
-Employed isotope labeling and manual microdissection.
-Findings published in journals of J.NCI and Can Letters.
-Work awarded “one of the top ten achievements in cancer research” in 2000 by the Ministry of Human Health.

The genetic instability analysis in the process of myelodysplastic syndromes evolving into leukemia
-Member of team performing pioneering research of genomic instability study using PCR in the process of MDS (pre-leukemia) evolving into acute myeloblastic leukemia.
-Bcl-2 and c-erbB2 expression in MDS by in situ hybridization and immunocytochemistry.
-Findings published in leukemia.

Education:
Certificate in Bioinformatics, UCSC-extension 2002
Postdoctoral Fellow, Stanford University, Stanford CA 2002
PhD, Pathology and Molecular Oncology, Chinese Academy of Medical Sciences, Beijing, China 1999
Dissertation: Allelotyping of primary TCC of bladder in Chinese.
MS, Cell Biology, Chinese Academy of Medical Sciences, Beijing, China 1996
Thesis: Microsatellite instability in the evolution of MDS and leukemia patients.
BS, Biology, Hebei Normal University, Shijiazhuang, China 1993

Affiliations:
·The Member of American Association for Cancer Research, 2001-2003.
·The Member of American Urological Association, 2004-2005

Skills:
Research Scientist bringing more than 11 years experience in urinary oncology diagnostics. Focused on finding new prostate cancer biomarkers through high-throughput oligonucleotide microarray, 2-D DIGE proteomics, and DNA genotyping. Awarded two patents on prostate cancer biomarkers.

2-D Difference Gel Electrophoresis (DIGE)
Oligonucleotide Microarray technology
Mass Spectrometry data analysis Quantitative-PCR technology
Protein analysis with WB, IHC and ELISA PCR for DNA polymorphism and SNP
Laser Capture Microdissection
RNA in situ hybridization and miRNA

Additional Information:
MAJOR PUBLICATIONS
1. Fan Z, Chen Z, Nolley R, McNeal J, Chien A, Guzzetta A, Peehl DM and Stamey TA. Proteome analysis of Benign Prostatic Hyperplasia and Malignant Prostate Tissue by two-dimensional difference gel electrophoresis and mass spectrometry (to be submitted to Proteomics)
2. Rose A, Xu Y, Chen.Z, Fan Z, Stamey TA, Peehl DM. Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer. Cancer Letters 2005, 227:213-222.
3. Stamey TA, Caldwell MC, Fan Z, Zhang Z, McNeal JE, Nolley R, Chen Z, Mahadevappa M, Warrington JA. Genetic profiling of Gleason grade 4/5 prostate cancer: which is the best prostatic control tissue? J Urol. 2003 Dec;170 (6 Pt 1):2263-8.
4.Chen Z, Fan Z (co-first author), John E. McNeal, et. al. Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol. 2003 Apr;169(4):1316-9.
5. Thomas A.Stamey, Janet A.Warrington, Mitchell C. Caldwell, Zuxiong Chen, Zhenbin Fan, et al. Molecular genetic profiling of Gleason grade 4/5 prostate cancers versus benign prostatic hyperplasia. Journal of Urology, 2001,166: 2171-2177.
6. Zhang J, Zheng S, Fan Z (co-first author), et al. A comparison between microsatellite analysis and routine cytology to detect bladder cancer. Cancer Letter, 2001, 172: 55-58.
7. Zhang J, Fan Z, et al. Detecting bladder cancer in the Chinese by microsatelite analysis: Ethic and etiologic considerations. Journal of National Cancer Institute. 2001, 93: 45-50.
8. Fan Z, Zhang J, Bai J, et al. 9p microsatellite instability analysis in tumor tissues and urinal cells of 26 cases bladder transitional cell carcinomas. National Medical Journal of China, 2000, 80 (1): 44-45
9. Fan Z. Allelotyping of primary TCC of bladder in Chinese. 1999, PUMC & CAMS Publisher Inc.
10. Fan Z, Zhang J, Bai J, et al. Deletion mapping of 18q and Smad proteins expression analysis in bladder carcinomas. Chinese Journal of Oncology, 2001, 23(2): 135-137.
11. Fan Z, Bai J, Cheng S. A report of microsatellite instability in Chinese primary bladder cancer. Chinese Cancer Report. 5 (1): 249, 1999.
12. Fan Z, Song Y, Cai H, et al. Microsatellite instability in the evolution of MDS patients. Leukemia, 1998, 7(3): 152-155.
13. Kong Xiang-yin, Zheng Guoguang, Zhenbin Fan, et al. Significance of c-erbB expression in marrow cells of myelodysplastic syndrome (MDS) patients. Chinese J. of Experimental Hematology 1994, 2 (3): 285-288.
14. Rao Q, Fan Z, Wu K. Isolation and characterization of membrane associated regulating factor from human leukemia cell line J6-1. Chinese J. of Experimental Hematology 1994, 2(3):257-261.

PATENTS
Two patents of prostate cancer diagnostics were approval.

Reference:
Available upon request

Candidate Contact Information:

Name: Zhenbin (John) Fan
Street: -	Phone: 650-962-9662
City: Mountain View	Fax: -
State: California
Zip: 94040
Web Site: